Literature DB >> 26643337

Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling.

Esther J H Janssen1, Pyry A J Välitalo1, Karel Allegaert2, Roosmarijn F W de Cock1, Sinno H P Simons3, Catherine M T Sherwin4, Johan W Mouton5, Johannes N van den Anker6, Catherijne A J Knibbe7.   

Abstract

Because of the recent awareness that vancomycin doses should aim to meet a target area under the concentration-time curve (AUC) instead of trough concentrations, more aggressive dosing regimens are warranted also in the pediatric population. In this study, both neonatal and pediatric pharmacokinetic models for vancomycin were externally evaluated and subsequently used to derive model-based dosing algorithms for neonates, infants, and children. For the external validation, predictions from previously published pharmacokinetic models were compared to new data. Simulations were performed in order to evaluate current dosing regimens and to propose a model-based dosing algorithm. The AUC/MIC over 24 h (AUC24/MIC) was evaluated for all investigated dosing schedules (target of >400), without any concentration exceeding 40 mg/liter. Both the neonatal and pediatric models of vancomycin performed well in the external data sets, resulting in concentrations that were predicted correctly and without bias. For neonates, a dosing algorithm based on body weight at birth and postnatal age is proposed, with daily doses divided over three to four doses. For infants aged <1 year, doses between 32 and 60 mg/kg/day over four doses are proposed, while above 1 year of age, 60 mg/kg/day seems appropriate. As the time to reach steady-state concentrations varies from 155 h in preterm infants to 36 h in children aged >1 year, an initial loading dose is proposed. Based on the externally validated neonatal and pediatric vancomycin models, novel dosing algorithms are proposed for neonates and children aged <1 year. For children aged 1 year and older, the currently advised maintenance dose of 60 mg/kg/day seems appropriate.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26643337      PMCID: PMC4750654          DOI: 10.1128/AAC.01968-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  63 in total

1.  Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.

Authors:  Toshimi Kimura; Keisuke Sunakawa; Nobuo Matsuura; Hiroaki Kubo; Shigehiko Shimada; Kazuo Yago
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

2.  Amikacin maturation model as a marker of renal maturation to predict glomerular filtration rate and vancomycin clearance in neonates.

Authors:  Wei Zhao; Valérie Biran; Evelyne Jacqz-Aigrain
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

3.  Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination.

Authors:  Yoke-Lin Lo; Johan G C van Hasselt; Siow-Chin Heng; Chin-Theam Lim; Toong-Chow Lee; Bruce G Charles
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

4.  Individualized dosing regimens in children based on population PKPD modelling: are we ready for it?

Authors:  Catherijne A J Knibbe; Meindert Danhof
Journal:  Int J Pharm       Date:  2011-03-03       Impact factor: 5.875

5.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  The influences of renal function and maturation on vancomycin elimination in newborns and infants.

Authors:  E V Capparelli; J R Lane; G L Romanowski; E J McFeely; W Murray; P Sousa; C Kildoo; J D Connor
Journal:  J Clin Pharmacol       Date:  2001-09       Impact factor: 3.126

7.  Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance.

Authors:  Brian J Anderson; Karel Allegaert; John N Van den Anker; Veerle Cossey; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2006-07-21       Impact factor: 4.335

8.  Improved vancomycin dosing in children using area under the curve exposure.

Authors:  Jennifer Le; John S Bradley; William Murray; Gale L Romanowski; Tu T Tran; Natalie Nguyen; Susan Cho; Stephanie Natale; Ivilynn Bui; Tri M Tran; Edmund V Capparelli
Journal:  Pediatr Infect Dis J       Date:  2013-04       Impact factor: 2.129

9.  A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates.

Authors:  Roosmarijn F W De Cock; Karel Allegaert; Catherine M T Sherwin; Elisabet I Nielsen; Matthijs de Hoog; Johannes N van den Anker; Meindert Danhof; Catherijne A J Knibbe
Journal:  Pharm Res       Date:  2013-09-25       Impact factor: 4.200

10.  Renal drug clearance in preterm neonates: relation to prenatal growth.

Authors:  Karel Allegaert; Brian J Anderson; John N van den Anker; Sophie Vanhaesebrouck; Francis de Zegher
Journal:  Ther Drug Monit       Date:  2007-06       Impact factor: 3.681

View more
  15 in total

1.  Larger Dose Reductions of Vancomycin Required in Neonates with Patent Ductus Arteriosus Receiving Indomethacin versus Ibuprofen.

Authors:  S Cristea; K Allegaert; A C Falcao; F Falcao; R Silva; A Smits; C A J Knibbe; E H J Krekels
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Population Pharmacokinetic Analysis and Dose Regimen Optimization in Japanese Infants with an Extremely Low Birth Weight.

Authors:  Hiroshi Sasano; Kanon Aoki; Ryutarou Arakawa; Kazuhiko Hanada
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

3.  Vancomycin dosing and therapeutic drug monitoring practices: guidelines versus real-life.

Authors:  Tatjana Van Der Heggen; Franky M Buyle; Barbara Claus; Annemie Somers; Petra Schelstraete; Peter De Paepe; Sophie Vanhaesebrouck; Pieter A J G De Cock
Journal:  Int J Clin Pharm       Date:  2021-04-28

4.  Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants.

Authors:  Yewei Chen; Dan Wu; Min Dong; Yiqing Zhu; Jinmiao Lu; Xiaoxia Li; Chao Chen; Zhiping Li
Journal:  Eur J Clin Pharmacol       Date:  2018-03-30       Impact factor: 2.953

Review 5.  The Relationship Between Vancomycin Trough Concentrations and AUC/MIC Ratios in Pediatric Patients: A Qualitative Systematic Review.

Authors:  Stacey Tkachuk; Kyle Collins; Mary H H Ensom
Journal:  Paediatr Drugs       Date:  2018-04       Impact factor: 3.022

6.  AUC- vs. Trough-Guided Monitoring of Vancomycin in Infants.

Authors:  Abdullah Alsultan; Manal Abouelkheir; Ahmad Albassam; Emad Alharbi; Ahmed Assiri; Saeed Alqahtani
Journal:  Indian J Pediatr       Date:  2020-01-27       Impact factor: 1.967

7.  Dosing antibiotics in neonates: review of the pharmacokinetic data.

Authors:  Nazario D Rivera-Chaparro; Michael Cohen-Wolkowiez; Rachel G Greenberg
Journal:  Future Microbiol       Date:  2017-07-31       Impact factor: 3.553

8.  A population pharmacokinetic model for individualised dosage regimens of vancomycin in Chinese neonates and young infants.

Authors:  Lin Song; Cui-Yao He; Nan-Ge Yin; Fang Liu; Yun-Tao Jia; Yao Liu
Journal:  Oncotarget       Date:  2017-10-26

9.  Vancomycin Dosage and Its Association with Clinical Outcomes in Pediatric Patients with Gram-Positive Bacterial Infections.

Authors:  Sooyoung Shin; Hyun Joo Jung; Sang-Min Jeon; Young-Joon Park; Jung-Woo Chae; Hwi-Yeol Yun
Journal:  Risk Manag Healthc Policy       Date:  2020-06-29

10.  Specialty Grand Challenge In Pediatric Infectious Diseases.

Authors:  Philippe Lepage; Sophie Blumental
Journal:  Front Pediatr       Date:  2017-08-28       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.